Compare ANIX & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIX | TMCI |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.5M | 120.4M |
| IPO Year | 2013 | 2021 |
| Metric | ANIX | TMCI |
|---|---|---|
| Price | $3.39 | $4.41 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 6 |
| Target Price | ★ $8.67 | $4.77 |
| AVG Volume (30 Days) | 282.9K | ★ 1.1M |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $210,000.00 | ★ $212,690,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.59 |
| 52 Week Low | $2.32 | $1.17 |
| 52 Week High | $5.46 | $7.78 |
| Indicator | ANIX | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 62.87 | 55.44 |
| Support Level | $2.90 | $3.84 |
| Resistance Level | $3.53 | $4.62 |
| Average True Range (ATR) | 0.28 | 0.37 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 79.92 | 60.11 |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.